Search Menu
Photonics Media Photonics Buyers' Guide Photonics EDU Photonics Spectra BioPhotonics EuroPhotonics Industrial Photonics Photonics Showcase Photonics ProdSpec Photonics Handbook
More News
Email Facebook Twitter Google+ LinkedIn Comments

Coherent Gets FDA Approvable Letterfor Laser AMD Treatment
Feb 2000
SANTA CLARA, Calif., Feb. 16 -- Coherent Inc. has received an approvable letter from the US Food and Drug Administration (FDA) for the Opal Photoactivator and Visudyne (Verteporfin for injection) therapy to treat the wet form of age-related macular degeneration (AMD). The disease is the leading cause of blindness in people over the age of 50 in the western world.
According to Coherent, the FDA has indicated that it will, following final review, approve the Opal Photoactivator, having concluded that Visudyne therapy is most appropriate for patients with the wet form of AMD, which is characterized by the presence of predominantly classic subfoveal choroidal neovascularization. This was the indication sought in the joint drug/device submission.
The FDA application for Visudyne therapy was filed jointly by Coherent and QLT PhotoTherapeutics Inc.; it covers Coherent's new Opal Photoactivator laser -- which the company said was developed specifically for use in photodynamic therapy -- and Verteporfin for injection, the drug that is activated by the special purpose 689-nm diode laser. Upon commercialization, the drug will be marketed worldwide by CIBA Vision Corp., the eye care unit of Novartis AG. Coherent will handle worldwide marketing of the Opal laser.

diode lasersNews & Featureslasers

Terms & Conditions Privacy Policy About Us Contact Us
back to top
Facebook Twitter Instagram LinkedIn YouTube RSS
©2018 Photonics Media, 100 West St., Pittsfield, MA, 01201 USA,

Photonics Media, Laurin Publishing
x We deliver – right to your inbox. Subscribe FREE to our newsletters.
We use cookies to improve user experience and analyze our website traffic as stated in our Privacy Policy. By using this website, you agree to the use of cookies unless you have disabled them.